Stem Cell Clinic

An ancient virus might have made our hearts bigger – Scope – Scope

By Stem Cell Medicine

A Stanford-led study finds that remnants of an ancient viral infection may be the reason humans and other primates evolved to have larger hearts and bodies.

Lately I've been thinking a lot about the Grinch. You know, the one who stole Christmas by taking away everything fun and good? (Shades of 2020, anyone?) The story goes that the Grinch's heart grew three sizes when the inhabitants of Whoville showed him the true meaning of the holiday. (Hint: it is love for one another in the face of adversity.)

Although it didn't happen in a matter of moments, humans and other large primates saw a similarly dramatic increase in heart size as they evolved from smaller primates. It's thought that the increased blood pumping ability may have contributed to our relatively larger body size.

Now, Stanford Medicine pathology instructor Kitchener Wilson, PhD, together with cardiologist Joseph Wu, MD, PhD, graduate student Mohamed Ameen and instructor Hongchao Guo, PhD, have come up with a reason for this Grinch-like transformation. They recently published their findings in Developmental Cell.

The culprit looks to be a remnant of an ancient viral infection in the form of a DNA sequence called BANCR that has piggybacked in our genomes for millions of years.

These viral fossils aren't rare. As Wilson explained:

About 10% of our genome is made up of these remains of viral infections in the form of pieces of DNA known as endogenous retroviruses. In fact, these viral sequences make up about five times more of our DNA than the genes that encode for actual proteins.

Normally, retroviruses insert their genetic material into the genomes of their host cells and just coast there until it's time to pop out and make new virus particles. Every time the host cell replicates its own genome, it also copies the stealthy invader and passes it along to the daughter cells. Occasionally these viruses infect egg or sperm cells. After fertilization, the developing embryo carries the inserted viral sequence in all of its cells.

For many years, it was thought that these DNA hitchhikers were just that -- freeloaders that didn't have much to do with the host cell's development or function. But more recently, it's become clear that some of these sequences are important in the expression of nearby genes, particularly in developing or cancerous cells.

As Wilson explained:

We became interested in an endogenous retroviral sequence called BANCR, which other than in some cancers, is active only in developing heart muscle cells in humans and larger primates like gorillas. Because the original viral infection occurred in a small primate ancestor, BANCR is not found in mice or other non-primates. We used induced pluripotent stem cell technology to study the effect of BANCR expression in developing heart muscle cells from humans, chimpanzees, gorillas and rhesus macaques, and found that it likely plays a role in cell migration during development.

There are intriguing hints that this effect on cell migration affects heart size. When Wilson artificially introduced BANCR in embryonic mice, the animals developed hearts with larger-than-normal left ventricles. Injecting a virus expressing BANCR into rat hearts also caused the heart to dilate under certain experimental conditions.

Finally, children with a rare condition called dilated cardiomyopathy, in which the heart is abnormally large and functions poorly, express higher-than-normal levels of BANCR. The researchers are cautiously hopeful that their findings may someday lead to future therapies for the life-threatening condition.

"Now we have a number of pieces of evidence that this retroviral sequence specifically affects heart size and function," said Wilson. "We've seen this ancient viral infection occurred in our primate ancestors, and subsequently all primates with this sequence have gotten larger. It's a provocative idea."

Photo by Debra

Infectious disease

Stanford ENT surgeon discusses how viruses cause a loss of sense of smell, and what you should do about it in the era of the coronavirus pandemic.

Aging

A Stanford dermatologist weighs in on using retinol to fight aging, acne and other skin problems, and whether it deserves the hype.

Link:
An ancient virus might have made our hearts bigger - Scope - Scope

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market: New Investment Opportunities Emerge to Augment Segments in Sector by 2026 – The…

By Platelet Rich Plasma Injections

In this report, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601860&source=atm

The major players profiled in this Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report include:

The key players covered in this study Orange County Hair Restoration Center Hair Sciences Center of Colorado Anderson Center for Hair Evolution Hair Loss Institute Savola Aesthetic Dermatology Center Virginia Surgical Center Hair Transplant Institute of Miami Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into Platelet Rich Plasma Injections Stem Cell Therapy Market segment by Application, split into Dermatology Clinics Hospitals

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players. To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601860&licType=S&source=atm

The study objectives of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report are:

To analyze and research the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601860&source=atm

Continued here:
Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market: New Investment Opportunities Emerge to Augment Segments in Sector by 2026 - The...

Platelet Rich Plasma Market 2020: Share Value Analysis of Top Key Players, Global Size, Consumption Analysis, Trends Forecast to 2024 | Industry…

By Platelet Rich Plasma Injections

The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.

Platelet Rich Plasma market report presents in-depth analysis regarding the development, current trends, industry policies, and regulations implemented in each of the geographical regions. It includes analysis of upstream raw materials, downstream demand, and current market dynamics. Furthermore, the Platelet Rich Plasma market report provides an in-depth insight into Platelet Rich Plasma industry during 2020-2024.

Scope of the Report:

As per the , platelet-rich plasma (PRP) prolotherapy, like dextrose prolotherapy, is a method of injection designed to stimulate healing. Platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels, which contains at least seven growth factors.

Inquire or Share Your Questions If Any Before the Purchasing This Report https://www.industryresearch.co/enquiry/pre-order-enquiry/13999558

Key Market Trends:

Pure PRP Segment by Type is Expected to Hold the Largest Market Share

The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.

The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.

Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.

North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years

North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US governments initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.

Reasons to Buy Platelet Rich Plasma Market Report:

Purchase this Report (Price 4250 USD for a Single-User License) https://www.industryresearch.co/purchase/13999558

Platelet Rich Plasma Market Report Covers the Following Questions:

Detailed TOC of Platelet Rich Plasma Market 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Incidences of Sports Injuries 4.2.2 Increasing Number of Androgenic Alopecia Patients 4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas 4.2.4 Rising Prevalence of Arthritis 4.3 Market Restraints 4.3.1 Stringent Regulatory Policies 4.3.2 High Prices of Plasma Therapy 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Type 5.1.1 Pure PRP 5.1.2 Leukocyte-rich PRP 5.1.3 Pure Platelet-rich Fibrin 5.1.4 Leukocyte-rich Fibrin 5.2 By Source 5.2.1 Autologous 5.2.2 Allogenic 5.3 By Application 5.3.1 Orthopedic 5.3.1.1 Arthritis 5.3.1.2 Chronic Tendinitis 5.3.1.3 Bone Repair and Regeneration 5.3.2 Dermatology 5.3.2.1 Androgenic Alopecia 5.3.2.2 Plastic Surgery 5.3.2.3 Cardiac Muscle Injury 5.3.2.4 Dental 5.3.2.5 Nerve Injury 5.3.2.6 Other Applications 5.3.3 By End User 5.3.3.1 Hospitals and Clinics 5.3.3.2 Research Institutes 5.3.3.3 Other End Users 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Bio Product Laboratory Ltd (BPL) 6.1.2 Biolife Plasma Services 6.1.3 Biotest AG 6.1.4 Cambryn Biologics LLC 6.1.5 China Biologic Products Inc. 6.1.6 CSL Ltd 6.1.7 Grifols International SA 6.1.8 Kedrion SpA 6.1.9 LFB SA 6.1.10 Octapharma AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Contact Center Outsourcing Market Size 2020 | Segmentation by Growth Trends, Latest Innovations, Future Demand Status, Business Share Forecast to 2024 Report by Industry Research.co

Stick Welders Market Growth by Forthcoming Developments 2020 Global Industry Scope, Future Prospects, Manufacturers with Size and Share Analysis till 2026 | Report by Industry Research.co

Emergency Shut Down Valves (ESDV) Market Business Growth Analysis with COVID-19 Impact, Future Trends, Industry Size, Global Share and Demand Status Forecast to 2026 Available at Industry Research.co

Valve Manifold Box (VMB) Market Size and Share Analysis 2020 Global Future Growth Rate, Industry Players, Developments Status, Trends Forecast to 2026 | Industry Research.co

Liquid Crystal on Silicon Projector Market Growth by Forthcoming Developments 2020 Global Industry Scope, Future Prospects, Manufacturers with Size and Share Analysis till 2026 | Report by Industry Research.co

Distillation Packings Market Growth Dynamics 2020 Outlook by Global Size and Share | Segmentation Analysis and Impact of COVID-19 on Global Industry Forecast to 2026

Automotive NFC System Market Share, Size 2020 Industry Analysis by Future Demand Status, Global Research, Top Leading player, Emerging Trends, Region by Forecast to 2025

Portable Medical and Healthcare Devices Market Analysis 2020 by Top Key Players, Key Factors, Global Industry Overview by Future Trends, Latest Scope, Business Advancement, and Forecast to 2026

More:
Platelet Rich Plasma Market 2020: Share Value Analysis of Top Key Players, Global Size, Consumption Analysis, Trends Forecast to 2024 | Industry...

New orthopedic provider joins team in Big Rapids – The Pioneer

By Platelet Rich Plasma Injections

Timothy Jelsema now seeing patients

, Submitted to the Pioneer

New orthopedic provider joins team in Big Rapids

BIG RAPIDS Orthopedic physician Timothy Jelsema, MD, MPH, recently joined the growing orthopedic medical team at Spectrum Health Big Rapids Hospital.

Jelsema joins Melissa DeNiel, MD, James Thiel, DO, and Jonathan Russell, PA-C, to provide comprehensive orthopedic care and surgical services to patients in the greater Big Rapids area.

Jelsema specializes in non-operative orthopedic care and sports medicine.

He will be treating patients non-surgically with various musculoskeletal conditions such as strains, sprains, fractures, concussions, and other sports or non-sports-related injuries.

Jelsema will also perform ultrasound-guided injections, platelet rich plasma therapy and tenotomy.

He believes in partnering with patients to choose the right treatment plan.

Im very big into shared decision making with the patient, Jelsema said. I like to set goals together and set a treatment path that makes each patient feel comfortable.

Jelsema recently completed a year as a sports medicine fellow at Henry Ford Health Systems in Detroit where he worked with Detroit Pistons, Detroit Tigers and Detroit City FC professional athletes.

He also provided medical support for all sports at Wayne State University and Allen Park High School.

In Big Rapids, he will work with Dr. DeNiel as team doctor for Ferris State University athletic teams.

A Grandville native, Jelsema received his bachelors degree from Calvin College. He earned masters degrees in medical science and public health along with his medical degree from Wayne State University.

He completed three years of residency training at Mercy Health St. Marys in Grand Rapids

Jelsema enjoys running, swimming, fly-fishing and playing recreational sports. He and his wife Cassie have relocated to Big Rapids with their two dogs.

To make an appointment with Jelsema, call Spectrum Health Big Rapids Hospital Orthopedics at 231-592-1002.

The rest is here:
New orthopedic provider joins team in Big Rapids - The Pioneer

Stem Cell Manufacturing Market Likely to Experience a Tremendous Growth in Near Future || Thermo Fis – PharmiWeb.com

By Stell Cell Research

DBMR has added a new report titledGlobal Stem Cell Manufacturing Marketwith data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Global Stem Cell Manufacturing Market report is quite useful to find out the general market conditions and tendencies. It also estimates the probable market for a new product to be launched in the market. This also Report has compiled to provide various market aspects such as size, share, trends, dynamics, growth, sales, and industry analysis. The competitive analysis taken place in this Global Stem Cell Manufacturing Market report include strategic profiling of key market players, their core competencies, their strong and weak points, and competitive landscape of the market which supports businesses illustrate their individual strategies.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Market Analysis and Insights: Global Stem Cell Manufacturing Market

Stem cell manufacturing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.59 billion by 2027 growing at a CAGR of 6.42% in the above-mentioned forecast period. The growing awareness towards diseases like cancer, hematopoietic disorders and degenerative disorders is going to drive the growth of the stem cell manufacturing market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market&pm

The Objective of This Report:

The Global Stem Cell Manufacturing Market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the Global Stem Cell Manufacturing Market. The report focuses on well-known providers in the Global Stem Cell Manufacturing Market industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Global Stem Cell Manufacturing Market Industry will develop is also analyzed in detail in this report.

Competitive Landscape and Stem Cell Manufacturing Market Share Analysis

Stem cell manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to stem cell manufacturing market.

The major players covered in the stem cell manufacturing market report are Thermo Fisher Scientific., Merck KGaA, BD, JCR Pharmaceuticals Co., Ltd., Organogenesis Inc, Osiris, Vericel Corporation, AbbVie Inc., AM-Pharma B.V., ANTEROGEN.CO.,LTD., Astellas Pharma Inc., Bristol-Myers Squibb Company, FUJIFILM Cellular Dynamics, Inc., RHEACELL GmbH & Co. KG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ViaCyte,Inc., VistaGen Therapeutics Inc, GlaxoSmithKline plc, DAIICHI SANKYO COMPANY, LIMITED, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Increase in the research and development activities in pharmaceutical and biotechnology sector, stem cell therapy including cell therapy and gene therapy along with animal biotechnology sector for the production of better yield is likely to accelerate the growth of the stem cell manufacturing market in the forecast period of 2020-2027.

People ethics such as the embryonic stem cell research violates respect for human life and downward pricing of product owing to commodity is likely to hamper the growth of the stem cell manufacturing market in the above mentioned forecast period.

Global Stem Cell Manufacturing Market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations in the market.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Stem Cell Manufacturing Market Country Level Analysis

Stem cell manufacturing market is analysed and market size insights and trends are provided by country, product, application and end users as referenced above.

The countries covered in the stem cell manufacturing market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the stem cell manufacturing market due to growing research in stem cell, robust research infrastructure, rising public-private funding, permission to support the clinical evaluation of stem cells for various applications along with rising public awareness on the therapeutic potency of stem cells, while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to the ongoing expansion & innovation of healthcare infrastructure across emerging Asian countries, the presence of supportive regulatory frameworks for stem cell research and manufacturing, and growing public-private initiatives to encourage public awareness about stem cell-based treatment.

The country section of the stem cell manufacturing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

Table of Contents:

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-manufacturing-market&pm

Insights of the Market in Report

1. The study provides an in-depth analysis of the Global Stem Cell Manufacturing Market along with the current trends and future estimations to elucidate the imminent investment pockets. 2. Comprehensive analysis of the factors that drive and restrict the market growth is provided in the report. 3. Comprehensive quantitative analysis of the industry is provided for the period of 2018-2025 to assist stakeholders to capitalize on the prevailing market opportunities. 4. Extensive analysis of the key segments of the industry helps in understanding the trends in types of Global Stem Cell Manufacturing Market across Glob. 5. Key market players and their strategies have been provided to understand the competitive outlook of the Global Stem Cell Manufacturing Market industry

Customization Available: Global Stem Cell Manufacturing Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Note: If You Have Any Special Requirements, Please Let Us Know and We Will Offer You the Report as You Want.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Excerpt from:
Stem Cell Manufacturing Market Likely to Experience a Tremendous Growth in Near Future || Thermo Fis - PharmiWeb.com

Hematopoietic Stem Cell Transplantation (HSCT) Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or…

By Stell Cell Research

Global Hematopoietic Stem Cell Transplantation (HSCT) industry report about In-depth Research, estimates Revenue, and forecasts Growth Details in segments, regional, and research scope, historical data, Key Player and Growth Value.

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 analysis provides a basic summary of the trade as well as definitions, classifications, applications and business chain structure. The worldwide Hematopoietic Stem Cell Transplantation (HSCT) marketing research is provided for the international markets together with development trends, competitive landscape analysis, and key regions development standing. Development policies and plans are mentioned similarly as producing processes and value structures are analyzed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

Premium Insights on Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 with Market Players Positioning Get Exclusive Sample PDF Copy:https://inforgrowth.com/sample-request/6544617/hematopoietic-stem-cell-transplantation-hsct-marke

Major Classifications of Hematopoietic Stem Cell Transplantation (HSCT) Market:

Major Key players covered in this report:Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc.

By Product Type:Allogeneic, Autologous

By Applications:Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT), Cord Blood Transplant (CBT)

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List https://inforgrowth.com/discount/6544617/hematopoietic-stem-cell-transplantation-hsct-marke

Impact of COVID-19: Hematopoietic Stem Cell Transplantation (HSCT) Market report analyses the impact of Coronavirus (COVID-19) on the Hematopoietic Stem Cell Transplantation (HSCT) industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Hematopoietic Stem Cell Transplantation (HSCT) market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of Hematopoietic Stem Cell Transplantation (HSCT) Market 2020. https://inforgrowth.com/CovidImpact-Request/6544617/hematopoietic-stem-cell-transplantation-hsct-marke

This Market Study covers the Hematopoietic Stem Cell Transplantation (HSCT) Market Size across segments. It aims at estimating the market size and the growth potential of the market across segments by component, data type, deployment type, organization size, vertical, and region. This Hematopoietic Stem Cell Transplantation (HSCT) study also includes an in-depth competitive analysis of the key market players, along with their company profiles, key observations related to product and business offerings, recent developments, and key market strategies.

Attributes such as new development in Hematopoietic Stem Cell Transplantation (HSCT) market, Total Revenue, sales, annual production, government norm, and trade barriers in some countries are also mentioned in detail in the report. Hematopoietic Stem Cell Transplantation (HSCT) Report discusses about recent product innovations and gives an overview of potential regional market shares.

Reason to purchase Hematopoietic Stem Cell Transplantation (HSCT) market report:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT: Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USA Contact Name: Rohan S. Email:[emailprotected] Phone: +1-909-329-2808 UK: +44 (203) 743 1898

Go here to see the original:
Hematopoietic Stem Cell Transplantation (HSCT) Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or...

Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University – BioSpace

By Stell Cell Research

BALTIMORE, Sept. 1, 2020 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development and commercialization of therapies for genetic diseases and vaccines, announced that Fujita Health University has received acontract from the Japan Agency for Medical Research and Development (AMED) to initiate Phase I/II clinical trials of the company's COVID-19 vaccine candidate, EXG-5003. Clinical trials are expected to begin at Fujita Health University Hospital in Aichi, Japan in Q1 2021.

EXG-5003 is a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. EXG-5003 was optimized for intradermal injection withpotential dose-sparing and safety benefits.

About Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company, which is focused on curing humanity's ailments through innovations in gene and cell therapy, including stem cell therapy. Elixirgen Therapeutics, Inc. is now applying its RNA technology to the development of a COVID-19 vaccine.For more information visit http://www.ElixirgenTherapeutics.com

About Fujita Health University

Fujita Health University plays a major role in treating COVID-19 patients and conducting its clinical trials in Japan. For more information visit http://www.fujita-hu.ac.jp/en/

Forward-Looking Statements

This press release may contain "forward-looking" statements, including statements regarding the potential to develop a COVID-19 vaccine and our planned clinical relationship with Fujita Health University. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in vaccine research and development. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statementsin the future, even if new information becomes available.

Contact Media Relations Elixirgen Therapeutics, Inc. (443) 869-5420 Media@ElixirgenTherapeutics.com

View original content:http://www.prnewswire.com/news-releases/elixirgen-therapeutics-planning-to-begin-phase-iii-clinical-trials-of-its-covid-19-vaccine-candidate-exg-5003-at-fujita-health-university-301121932.html

SOURCE Elixirgen Therapeutics

View original post here:
Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University - BioSpace

Cell Counting Market worth $14.5 billion by 2025 according to a new research report – WhaTech

By Stell Cell Research

The cell counting market is projected to reach USD 14.5 billion in 2025 from USD 10.4 billion in 2020, at a CAGR of 6.7 % during the forecast period.

The market growth is largely driven by factors such as growing funding for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematologyanalyzers. On the other hand, the high cost of cell analysis is expected to hinder market growth to a certain extent.

According to MarketsandMarkets - [247 Pages Report] The global cell counting market is projected to reach USD 14.5 billion in 2025 from USD 10.4 billion in 2020, at a CAGR of 6.7 % during the forecast period.

Cell Counting Market by Product (Instruments (Spectrophotometer, Hemocytometer, Flow Cytometer, HematologyAnalyzers), Consumables (Reagent, Microplate)), Cancer, Stem Cell Research, End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2025

Download a PDF Brochure @ http://www.marketsandmarkets.com/pdfdown=157450728

The medical application segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, the cell counting market is segmented into research, medical, and industrial applications. The medical application segment will grow at the highest CAGR in the cell counting market.

Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment during the forecast period.

The hospitals and diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period

On the basis of end users, the cell counting market is segmented into research institutes, hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and CROs, and other end users. The hospitals and diagnostic laboratories will grow at the highest CAGR during the forecast period.

The high growth of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R&D expenditure, and commercial expansion of various pharmaceutical companies.

Request a Sample Pages @ http://www.marketsandmarkets.com/request=157450728

The Asia Pacific region is expected to account for the largest share of the cell counting market during the forecast period

The APAC region is expected to grow at the highest CAGR during the forecast period. The large growth of this segment can be attributed to factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization.

Key Market Players

The major companies in the cell counting market include Thermo Fisher Scientific Inc (US), Merck KGaA (Germany), PerkinElmer Inc (US), Olympus Corporation (Japan), HORIBA Ltd (Japan), Logos BiosystemsInc (South Korea), Corning Incorporated (US), Tecan Trading AG (Switzerland), Abbott (US), General Electric Company (US), Boule Diagnostics AB (Sweden), Becton, Dickinson and Company (US), Tip Biosystems (Singapore), Agilent Technologies Inc (US), Sysmex Corporation (Japan), Siemens Healthcare Private Limited (Germany), Danaher (US), Diconex (Argentina), Beckman Coulter Inc (US), Nexcelom Bioscience LLC (US), ChemoMetec A/S (Denmark), Bio-Rad Laboratories Inc (US), Advanced Instruments (US), R&D Systems, Inc. (US), and Cole-Parmer Instrument Company LLC (US)

Recent Developments:

Speak to Analyst @ http://www.marketsandmarkets.com/speakto=157450728

This email address is being protected from spambots. You need JavaScript enabled to view it.

View original post here:
Cell Counting Market worth $14.5 billion by 2025 according to a new research report - WhaTech

Global Musculoskeletal Disorder Stem Cell Therapy Market 2020 Upcoming Trends, Latest Innovation, Advance Technology and Forecast 2025 – Owned

By Stell Cell Research

Global Musculoskeletal Disorder Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 combines the essentials, definitions, categorization, and analysis of significant features. A latest extensive, professional market study brings data on the Musculoskeletal Disorder Stem Cell Therapy market which is related to market competitors and recognized players for the forecast period from 2020 to 2025. The market study is segmented by, trends, latest analytics, top players, application usage, and various important geographical dividends. The beginning section of the report contains the basic detailed information about the concerned market. The report studies the worldwide markets vital regional market demands. It covers the analysis of market position and market size. Further, it provides a layout with regard to the market dynamics, by pinpointing several aspects comprising limitations, value chain, and drivers.

The various new and innovative manufacturing processes for the manufacturing of Musculoskeletal Disorder Stem Cell Therapy are being adopted by the market players on a large scale. The research helps you to achieve positive growth and allow different methods for maximizing your profit. Moving forward, the competitive landscape of the Musculoskeletal Disorder Stem Cell Therapy market in the world is given by profiling the major participants of the market in order to identify the leading players in the market. The study contains a general effective framework, restrictions, and a total explanation of the previous data close by the investigated present and future needs.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/36571

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Region Segment Analysis of the Market:

Based on segmentation, the global Musculoskeletal Disorder Stem Cell Therapy market report is made up of an in-depth investigation of the leading regions, including North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The research was provided including developments, leading growth status, landscape analysis, and segmentation with product types and applications. The cost-profit is broken down regionally, leading to analysis results that explain the market condition in a specific geographical area and can be used to make focused market policies. The number of crucial regions that the marketing research is finished in is North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). These are the top-grossing regions that have revealed the utmost development in each side of technology, businesses, population, industry, and more.

Some of the leading key companys covered for this research are Osiris Therapeutics, Medi-post, NuVasive, Takeda (TiGenix)

The report highlights product types which are as follows: llogeneic, Autologous, etc.

The report highlights top applications which are as follows: uscle disease, Skeletal disease, etc.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-musculoskeletal-disorder-stem-cell-therapy-market-36571

Reason to Buy Musculoskeletal Disorder Stem Cell Therapy Market Report:

Moreover, the report includes social and opinion research that comprises information about individuals or organizations. Marketing strategies and different channels have been listed here. It uncovers the gaps and opportunities to derive the most relevant insights from our research document to gain global Musculoskeletal Disorder Stem Cell Therapy market size.

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.researchstore.biz

Click Here For Similar Reports:

Global Axle Market 2020 Key Players Data, Revenue, Future Development, Trend and Competitive Landscape Analysis by 2025

Global Cocoa Butter Fats Market 2020 Key Players, Comprehensive Research, SWOT Analysis and Forecast by 2025

Global Foldable Walker Market 2020 Opportunities, Challenges, Key Players, Trend and Forecast by 2025

Global Foldable Baby Stroller Market 2020 Industry Analysis by Key Players, Product Type, Application, Regions and Forecast to 2025

View post:
Global Musculoskeletal Disorder Stem Cell Therapy Market 2020 Upcoming Trends, Latest Innovation, Advance Technology and Forecast 2025 - Owned

Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I – GlobeNewswire

By Stell Cell Research

September 01, 2020 07:00 ET | Source: Orchard Therapeutics (Europe) Limited

Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression

Translation of metabolic correction to clinical outcomes in first two patients continues to support potential of hematopoietic stem cell gene therapy in a second neurometabolic disorder

Data support planned initiation of registrational trial in 2021

BOSTON and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced additional interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an investigationalex vivoautologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at theSan Raffaele Telethon Institute for Gene Therapy(SR-Tiget) inMilan, Italy. The readout from the primary endpoint at one year of follow-up is expected in 2021. Today's results are being shared virtually in an invited oral presentation at the 46th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT).

We continue to see encouraging data from the ongoing clinical trial in MPS-I, including promising preliminary clinical effects on motor development, acquisition of cognitive skilIs and growth in the first two patients that were treated now 1.5 and 2 years ago, respectively. Additionally, new preliminary analyses of radiological outcome measures suggest that treatment with OTL-203 leads to stabilization or improvement in disease-related neurological abnormalities, as measured by brain and spine MRI, which we look to confirm with longer follow-up, saidMaria Ester Bernardo, M.D., Ph.D., principal investigator at SR-Tiget. "These data, taken together with those from clinical studies of HSC gene therapy for other metabolic disorders and leukodystrophies, support the potential for this therapeutic approach to correct a wide spectrum of multisystemic manifestations of the disease, bringing clinically meaningful benefits for patients.

Interim Study Results

Eight patients with the severe Hurler subtype of MPS-I had been treated with OTL-203 in the ongoing proof-of-concept study, which completed enrollment in December 2019. As of July 2020, all patients had been followed for a minimum of six months, with the longest follow-up extending out to 24 months. Treatment with OTL-203 was generally well-tolerated with a safety profile consistent with the selected conditioning regimen. Consistent with previous analyses, treatment across all eight patients continued to demonstrate:

We continue to see positive trends in all biomarker and clinical measures as we follow patients in the OTL-203 proof of concept study for longer periods of time, saidBobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. With a growing amount of data to support advancing this program, we have recently convened a panel of disease experts to develop a design for a registrational trial that we intend to take to the regulators in advance of initiating the study in 2021 and ultimately progressing towards commercialization.

About OTL-203 and MPS-I

Mucopolysaccharidosis type I (MPS-I) is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme, which is required to break down sugar molecules called glycosaminoglycans (also known as GAGs). The accumulation of GAGs across multiple organ systems results in symptoms including neurocognitive impairment, skeletal deformity, loss of vision and hearing, and cardiovascular and pulmonary complications. MPS-I occurs at an overall estimated frequency of one in every 100,000 live births. There are three subtypes of MPS-I; approximately 60 percent of children born with MPS-I have the most severe subtype, called Hurler syndrome, and rarely live past the age of 10 when untreated.

Treatment options for MPS-I include hematopoietic stem cell transplant and chronic enzyme replacement therapy, both of which have significant limitations. Though early intervention with enzyme replacement therapy has been shown to delay or prevent some clinical features of the condition, it has only limited efficacy on neurological symptoms. OTL-203 is an investigationalex vivoautologous hematopoietic stem cell gene therapy being studied for the treatment of MPS-I. Orchard was granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the gene therapy program for the treatment of MPS-I developed by theSan Raffaele Telethon Institute for Gene TherapyinMilan, Italy.

About Orchard

Orchard Therapeuticsis a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Ourex vivoautologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy inMilan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters inLondonandU.S.headquarters inBoston. For more information, please visitwww.orchard-tx.com, and follow us onTwitterandLinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (TwitterandLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, plans, intends, projects, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidates referred to in this release, Orchards expectations regarding the timing of clinical trials for its product candidates, including the product candidates referred to in this release, the timing of interactions with regulators and regulatory submissions related to ongoing and new clinical trials for its product candidates, the timing of announcement of clinical data for its product candidates, and the likelihood that such data will be positive and support further clinical development and regulatory approval of these product candidates. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs; the risk that Orchard will not realize the anticipated benefits of its new strategic plan or the expected cash savings associated with such plan; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be successfully developed, approved or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates or that long-term adverse safety findings may be discovered; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedJune 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com

Media Molly Cameron Manager, Corporate Communications +1 978-339-3378 media@orchard-tx.com

Here is the original post:
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I - GlobeNewswire

→←